Treatment of human immunodeficiency virus-related lymphoma with haematopoietic stem cell transplantation

Blood Reviews

Volumn 17, Issue 4, 2003, Pages 249-258

  Molina, Arturo ^a   Zaia, John ^a   Krishnan, Amrito ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Haematopoietic stem cell transplantation; Highly active antiretroviral therapy (HAART); HIV; Hodgkin's disease; Lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; EFAVIRENZ; ETOPOSIDE; IFOSFAMIDE; INDINAVIR; LACTATE DEHYDROGENASE; LAMIVUDINE; METHOTREXATE; MYELOABLATIVE AGENT; NELFINAVIR; NEVIRAPINE; POG 8617; POG 9317; POG 9517; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITONAVIR; RITUXIMAB; SAQUINAVIR; STAVUDINE; STREPTOZOCIN; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; VINCRISTINE SULFATE;

ADOLESCENT; ADULT; AGED; APHERESIS; BACTEREMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CHEMOSENSITIVITY; CLINICAL ARTICLE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; LEUKEMIA REMISSION; LYMPHOMA; MALE; MULTIPLE ORGAN FAILURE; OPPORTUNISTIC INFECTION; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SCHOOL CHILD; UNITED STATES;

EID: 0242354771     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(03)00026-2     Document Type: Review

References (88)

1. Centers for Disease Control. Revision of the case definition of acquired immunodeficiency syndrome for national reporting-United States. MMWR 1985; 34: 373-375.
2. Goedert J. Epidemiology of acquired immune deficiency syndrome malignancies. Sem Oncol 2000; 27: 390-401.
3. Levine AM. Acquired immune deficiency syndrome-related lymphoma: clinical aspects. Sem Oncol 2000; 27: 442-453.
4. Tulpule A, Levine A. AIDS-related lymphoma. Blood Rev 1999; 13(3): 147-150.
5. Gates AE, Kaplan LD. AIDS malignancies in the era of highly-active antiretroviral therapy (first of two parts). Oncology 2002; 16: 441-451, see also pp. 456, 459.
6. Desai J, Mitnick RJ, Henry DH, Llena J, Sparano JA. Patterns of central nervous system recurrence in patients with systemic human immunodeficiency virus-associated non-Hodgkin lymphoma. Cancer 1999; 86: 1840-1847.
7. Seneviratne L, Espina BM, Nathwani BN, Chan JA, Brynes RK, Levine AM. Clinical, immunologic, and pathologic correlates of bone marrow involvement in 291 patients with acquired immunodeficiency syndrome-related lymphoma. Blood 2001; 98: 2358-2363.
8. Molina A. Is Hodgkin's disease an AIDS-associated disease? (Commentary). Oncology 1987; I(8): 52.
9. Hessol NA, Katz MH, Liu JY et al. Increased incidence of Hodgkin's disease in homosexual men with HIV infection. Ann Intern Med 1992; 117: 309-311.
10. Tirelli U, Errante D, Dolcetti R et al. Hodgkin's disease and human immunodeficiency virus infection: clinicopathologic and virologic features off 114 patients from the Italian Cooperative Group on AIDS and tumors. J Clin Oncol 1995; 13: 1758-1767.
11. Levine AM. Hodgkin's disease in the setting of human immunodeficiency virus infection. J Natl Cancer Inst 1998; 23: 37-42.
12. Spina M, Vaccher E, Nasti G et al. Human immunodeficiency virus-associated Hodgin's disease. Sem Oncol 2000; 27: 480-488.
13. Gates AE, Kaplan LD. AIDS malignancies in the era of highly-active antiretroviral therapy (second of two parts). Oncology 2002; 16: 657-665, discussion 669-670.
14. Kaplan LD, Straus DJ, Testa MA et al. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. N Engl J Med 1997; 336: 1641-1648.
15. Remick SC, Sedransk H, Haase RF et al. Oral combination chemotherapy in conjunction with filgrastim (G-CSF) in the treatment of AIDS-related non-Hodgkin's lymphoma: evaluation of the role of G-CSF; quality-of-life analysis and long-term follow-up. Am J Hematol 2001; 66: 178-188.
16. Oksenhendler E, Gerard L, Dubreuil ML et al. Intensive chemotherapy (LNHIV-91 regimen) and G-CSF for HIV associated non-Hodgkin's lymphoma. Leukemia Lymphoma 2000; 39: 87-95.
17. Bower M, Stern S, Fife K, Nelson M, Gazzard BG. Weekly alternating combination chemotherapy for good prognosis AIDS-related lymphoma. Eur J Cancer 2000; 36: 363-367.
18. Wiernik PH. Treatment of human immunodeficiency virus-related lymphoma. Sem Hematol 2001; 38(Suppl 10): 27-31.
19. Remick SC, Sedransk H, Haase RF et al. Oral combination chemotherapy in the management of AIDS-related lymphoproliferative malignancies. Drugs 1999; 58(Suppl 3): 99-107.
20. Tirelli U, Errante D, Spina M et al. Second-line chemotherapy in HIV-related non-Hodgkin's lymphoma. Cancer 1996; 77: 2127-2131.
21. Levine A, Tupule A, Tessmman D et al. Mitoguazone therapy in patients with relapsed or refractory AIDS-related lymphoma: results from a multicenter phase II trial. J Clin Oncol 1997; 15: 1094-1103.
22. Spina M, Vaccher E, Juzbasic S et al. Human immunodeficiency virus-related non-Hodgkin lymphoma: activity of infusional cyclophosphamide, doxorubicin, and etoposied as second-line chemotherapy in 40 patients. Cancer 2001; 92: 200-206.
23. Bi J, Espina BM, Tulpule A, Boswell W, Levine AM. High-dose cytosine-arabinoside and cisplatin regimens as salvage therapy for refractory or relapse AIDS-related non-Hodgkin's lymphoma. J Acq Immun Def Synd 2001; 28: 416-421.
24. Palella FJ, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV oupatient study investigators. N Engl J Med 1998; 338: 853-860.
25. Mocroft A, Sabin CA, Youle M et al. Changes in AIDS-defining illnesses in a London Clinic, 1987-1998. J Acq Immun Def Synd 1999; 21: 401-407.
26. Sparano JA, Anand K, Desai J, Mitnick RJ, Kalkut GE, Hanau LH. Effect of highly active antiretroviral therapy on the incidence of HIV-associated malignancies at an urban medical center. J Acq Immun Def Synd 1999; 21: S18-S22.
27. Grulich AE. AIDS-associated NHL in the era of highly active antiretroviral therapy. J Acq Immun Def Synd 1999; 21: S27-S30.
28. Rabkin CS, Testa MA, Huang J, Roenn JH. Kaposi's sarcoma and non-Hodgklin's lymphoma incidence trends in AIDS Clinical Trial Group study participants. J Acq Immun Def Synd 1999; 21: S31-S33.
29. Mocroft A, Katama C, Johnson AM et al. AIDS across Europe 1994-1998: the EuroSIDA study. Lancet 2000; 356: 291-296.
30. Clarke CA, Glasser SL Epidemiologic trends in HIV-associated lymphomas. Curr Opin Oncol 2001; 13: 354-359.
31. Besson C, Goubar A, Gabarre J et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 2001: 2339-2344.
32. Biggar RJ. AIDS-related cancers in the era of highly active antiretroviral therapy. Oncology (Huntingt) 2001; 15: 439-448, discussion 448-449.
33. Grulich AE, Li Y, McDonald AM, Correll PK, Law MG, Kaldor JM. Decreasing rates of Kapos's sarcoma and non-Hodgkin's lymphoma in the era of potent combination anti-retroviral therapy. AIDS 2001; 15: 629-633.
34. Matthews GV, Bower M, Mandalia S et al. Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood 2000; 96: 2730-2734.
35. Buchbinder SP, Holmberg SD, Scheer S, Colfax G, O'Malley P, Vittinghoff E. Combination antiretroviral therapy and incidence of AIDS-related malignacies. J Acq Immun Def Synd 1999; 21: S23-S26.
36. Rabkin CS. AIDS and cancer in the era of highly active antiretroviral therapy (HAART). Eur J Cancer 2001; 37: 1316-1319.
37. Levine AM, Seneviratne L, Tulpule A. Incidence and management of AIDS-related lymphoma. Oncology (Huntingt) 2001; 15: 629-639, discussion 639-640, 645-646.
38. Dal Maso L, Serraino D, Franceschi S. Epidemiology of AIDS-related tumours in developed and developing countries. Eur J Cancer 2001; 37: 1188-1201.
39. Little RF, Gutierrez M, Jaffe ES, Pau A, Horne M, Wilson W. HIV-associated non-Hodgkin's lymphoma: incidence, presentation and prognosis. JAMA 2001; 285: 1880-1885.
40. Levine AM, Seneviratne L, Espina BM et al. Evolving characteristics of AIDS-related lymphoma. Blood 2000; 96: 4084-4090.
41. Vaccher E, Spina M, di Gennaro G et al. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin's lymphoma. Cancer 2001; 91: 155-163.
42. Ratner L, Lee J, Tang S et al. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 2001; 19: 2171-2178.
43. Navarro JT, Ribera JM, Oriol A et al. Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydrixydoxorubicin, vincristine and prednisone. Br J Haematol 2001; 112: 909-915.
44. Levine AM, Li P, Cheung T et al. Chemotherapy consisting of doxorubicin, bleomycin, vinblastine and dacarbazine with granulocyte-colony-stimulating factor in HIV-infected patients with newly diagnosed Hodgkin's disease: a prospective multi-institutional AIDS clinical Trials Group Study (ACTG 149). J Acq Immun Def Synd 2000; 24: 444-450.
45. Spina M, Gabarre J, Rossi G et al. Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood 2002; 100: 1984-1988.
46. Antinori A, Cingolani A, Alba L et al. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS 2001; 15: 1483-1491.
47. Powles T, Imani N, Nelson M, Gazzard BG, Bower M. Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-I associated lymphoma. AIDS 2002; 16: 531-536.
48. Molina A, Krishnan A, Nademanee A et al. High dose therapy and autologous stem cell transplantation for human immunodeficiency virus associated non-Hodgkin lymphoma in the era of highly active antiretroviral therapy. Cancer 2000; 89: 680-689.
49. Krishnan A, Molina A, Zaia J et al. Autologous stem cell transplantation for HIV-associated lymphoma. Blood 2001; 98: 3857-3859.
50. Gabarre L, LeBlond V, Sutton L et al. Autologous bone marrow transplantation in relapsed HIV-related non-Hodgkin's lymphoma. Bone Marrow Transpl 1996; 18: 1195-1197.
51. Ubel PA, Caplan AL. Solid-organ transplantation in HIV-infected patients. N Engl J Med 2002; 347: 284-287.
52. Contu L, LaNasa G, Arras M et al. Allogeneic bone marrow transplantation combined with multiple anti-HIV treatments in a case of AIDS. Bone Marrow Transpl 1993; 12: 669-671.
53. Ragni MV, Dodson SF, Hunt SC, Bontempo FA, Fung JJ. Liver transplantation in a hemophilia patient with acquired immunodeficiency syndrome. Blood 1999; 93: 1113-1114.
54. Gabarre J, Azar N, Autran B et al. High-dose therapy and autologous haematopoietic stem-cell transplantation for HIV-I-associated lymphoma. Lancet 2000; 355(9209): 1071-1072.
55. Lane HC, Zunich KM, Wilson W et al. Syngeneic bone marrow transplantation and adoptive transfer of peripheral blood lymphocytes combine with zidovudine in human immunodeficiency virus (HIV) infection. Ann Intern Med 1990; 113: 512-519.
56. Campbell P, Iland H, Gibson J, Joshua D. Syngeneic stem cell transplantation for HIV-related lymphoma. Br J Haematol 1999; 105: 795-798.
57. Tirelli U, Spina M, Jaeger U et al. Infusional CDE with rituximab for the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: preliminary results of a phase I/ll study. Recent Results Cancer Res 2002; 159: 149-153.
58. Schmidt-Wolf IG, Rockstroh JK, Schlegel U, Pels H, Weiss R, Huhn D. New aspects in the treatment of AIDS-related lymphoma. Eur J Med Res 2002; 7: 295-303.
59. Little RF, Pearson D, Steinberg S et al. Dose-adjusted EPOCH chemotherapy in previously untreated HIV-associated non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol 1999; 18: 10a (abstract 33).
60. Gisselbrecht C, Gabarre J, Spina M. Treatment of HIV-related non-Hodgkin's lymphoma adapted to prognostic factors. Proc Am Soc Clin Oncol 1999; 18: 16a (abstract 55).
61. Little RF, Yarchoan R, Wilson WF. Systemic chemotherapy for HIV-associated lymphoma in the era of highly active antiretroviral therapy. Curr Opin Oncol 2000; 12: 438-444.
62. Koka PS, Jamieson BD, Books DG, Zack JA. Human immunodeficiency virus type I-induced hematopoietic inhibition is independent of productive infection of progenitor cells in vivo. J Virol 1999; 73: 9089.
63. Schooley RT, Mladenovic J, Sevin A et al. Reduced mobilization of CD34+ stem cells in advance human immunodeficiency virus type-I disease. J Infect Dis 2000; 181: 148-157.
64. Levine AM, Scadden DT, Zaia JA, Krishnan A. Hematologic aspects of HIV/AIDS. Hematology (Am Soc Hematol Educ Program) 2001: 463-478.
65. Isgro A, Mezzaroma I, Aiuti A et al. Recovery of hematopoietic activity in bone marrow from human immunodficiency virus type-I infected patients during highly active antiretroviral therapy. AIDS Res Hum Retrov 2000; 16: 1471.
66. Gerard L, Galicier L, Maillard A et al. Systemic non-Hodgkin lymphoma in HIV-infected patients with effective suppression of HIV replication: persistent occurrence but improved survival. J Acq Immun Def Synd 2002; 30: 478-484.
67. Baiocchi OC, Colleoni GW, Navaias EV et al. Impact of highly active antiretroviral therapy in the treatment of HIV-infected patients with systemic non-Hodgkin's lymphoma. Acta Oncol 2002; 41: 192-196.
68. Krishnan A, Zaia JA, Molina A. Hematopoietic stem cell transplantation and gene therapy for HIV-associated lymphoma. J Hematoth Stem Cell Res 2002; 11: 765-775.
69. Krishnan A, Molina A, Zaia J, Vasquez D, Smith D, Forman SJ. Durable remissions in HIV-related lymphoma with autologous stem cell transplantation. Blood 2002; 100: 181a (abstract).
70. Krishan A, Molina A, Forman SJ. Organ transplantation in HIV-infected patients. N Engl J Med 2002; 347: 1801-1803, letter.
71. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987-994.
72. + peripheral blood stem cells from asymptomatic human immunodeficiency virus type-I infected individuals mobilized with granulocyte colony-stimulating factor. Blood 1997; 89: 4299-4306.
73. Bauer G, Valdez P, Kearns K et al. Inhibition of human immunodeficiency virus-I (HIV-1) replication after transduction of granulocyte colony-stimulating factor-mobilized CD34+ cells from HIV-I-infected donors using retroviral vectors containing anti-HIV-I genes. Blood 1997; 89: 2259-2267.
74. Nademanee A, Sniecinski I, Schmidt GM et al. High-dose therapy followed by autologous peripheral blood stem cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma utilizing unprimed and granulocyte colony-stimulating factor "mobilized" peripheral blood stem cells. J Clin Oncol 1994; 12: 2176-2186.
75. Nademanee A, Molina A, O'Donnell MR et al. Results of high-dose therapy and autologous bone marrow/stem cell transplantation in poor-risk intermediate and high-grade lymphoma. International Index high and high-intermediate risk group. Blood 1997; 90: 3844-3852.
76. Nademanee A, O'Donnell MR, Snyder DS et al. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with an analysis of prognostic factors. Blood 1995; 85: 1381-1390.
77. Molina A, Popplewell L, Kashyap A, Nademanee A. Hematopoietic stem cell transplantation in the new millennium: report from City of Hope National Medical Center. Clin Transpl 2000: 317-342.
78. Gabarre J, Choquet S, Azar N et al. High-dose chemotherapy (HDC) with autologus stem cell transplantation (AST) for HIV-related lymphoma (Ly): a single center report on 14 patients (pts). Blood 2001; 98(Suppl 1): 502a (abstract 2092).
79. Attal M, Huguet F, Rubie H et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low dose heparin: a prospective, randomized trial. Blood 1992; 79: 2834-2840.
80. Zaia JA, Rossi JJ, Kriahnan A et al. Autologous stem cell transplantation using retrovirus-transduced peripheral blood progenitor cells in HIV-infected persons: comparison of gene marking post-engraftment with and without myeloablative therapy. Blood 1999; 94(Suppl 1) (abstract 2850).
81. Kang EM, de Witte M, Malech H et al. Nonmyeloablative conditioning followed by transplantation of genetically modified HLA-matched peripheral blood progenitor cells for hematologic malignancies in patients with acquired immunodeficiency syndrome. Blood 2002; 99: 698-701.
82. Nademanee A, Molina A, Forman SJ et al. A phase I/II trial of high-dose radioimmunotherapy (RIT) with Zevalin in combination with high-dose etoposide (VP-16) and cyclophosphamide (CY) followed by autologous stem cell transplantation (ASCT) in patients with poor-risk or relapsed B-cell non-Hodgkin' lymphoma (NHL). Blood 2002; 100: 182a (abstract).
83. Horovitz S, Negrin RS, Stockerl-Goldstein KE et al. A phase II trial of rituximab as adjuvant therapy to high dose chemotherapy and peripheral blood stem cell transplantation for relapsed and refractory aggressive non-Hodgkin's lymphoma. Blood 2001; 98(Suppl 1): 862a (abstract 3578).
84. Biggar RJ, Engels EZ, Frisch M, Goedert JJ. Risk of T-cell lymphomas in persons with AIDS. J Acq Immun Def Synd 2001; 26: 371-376.
85. Philip T, Gugliermi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540-1545.
86. Haioun C, Lepage E, Gisselbrecht C et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol - groupe d'Etude des lymphomas de l'Adulte study. J Clin Oncol 2000; 18: 3025-3030.
87. Nademanee A, Molina A, Dagis A et al. Autologous stem cell transplantation for poor-risk and relapsed intermediate and high-grade non-Hodgkin's lymphoma. Clin Lymphoma 2000; 1: 46-54.
88. Molina A. Non-Hodgkin's Lymphoma. In: Pazdur R, Coia L, Wagman L, Hoskins W, eds. Cancer Management: A Multidisciplinary Approach, fifth ed. Huntington, NY: PRR; 2001: 583-620.